• Home
  • >
  • Mankind Pharma Ltd Financials
https://storage.googleapis.com/assets.cdp.blinkx.in/BlinkxSearch/initials/m.svg Logo

Mankind Pharma Ltd Financial Statement

Mankind Pharma Ltd Income Statement
Quarterly
Annual

*All values are in Rs. Cr

(Rs. CR)Mar 2024Dec 2023Sep 2023
Revenue2,236.542,425.82,511.46
Operating Expense1,605.351,755.461,818.15
Net Profit454.17487.07472.88
Net Profit Margin20.3120.0818.83
Earning Per Share11.3412.1611.8
EBIDTA651.14655.47676.48
Effective Tax Rate17.5311.117.63

(Rs. Cr)

Revenue

Operating Expense

Net Profit

Net Profit Margin

Earning Per Share

EBIDTA

Effective Tax Rate

Mankind Pharma Ltd Profit & Loss

*All values are in Rs. Cr

Consolidated
Standalone
ParticularsMar 2023Mar 2022Mar 2021
Total Revenue Annual8,749.437,781.566,214.43
Operating Expenses Annual6,848.85,792.24,566.33
Operating Profit Annual2,041.632,199.831,830.73
Interest Annual44.4758.6120.15
Depreciation167.08141.4104.88
Net Profit Annual1,281.861,433.481,265.43
Tax Annual361.56521.64398.58

Particulars

Total Revenue Annual

Operating Expenses Annual

Operating Profit Annual

Interest Annual

Depreciation

Net Profit Annual

Tax Annual

Mankind Pharma Ltd Cash Flow

*All values are in Rs. Cr

Consolidated
Standalone
ParticularsMar 2023Mar 2022Mar 2021
Cash Flow at the Beginning283.06127.33219.73
Cash Flow from Operations1,813.3919.781,137.24
Cash Flow from Investing-1,051.81-1,368.67-1,221.84
Cash Flow from Financing-739.73604.62-7.81
Cash Flow at the End304.82283.06127.33

Particulars

Cash Flow at the Beginning

Cash Flow from Operations

Cash Flow from Investing

Cash Flow from Financing

Cash Flow at the End

Mankind Pharma Ltd Key Ratios

*All values are in Rs. Cr

Consolidated
Standalone
ParticularsMar 2023Mar 2022Mar 2021
PBDIT Margin (%)23.3528.2929.48
PBIT Margin (%)19.6226.1427.56
PBT Margin (%)19.1625.6926.09
Net PROFIT Margin (%)15.3618.5619.63
Return On Networth / Equity (%)19.2726.7231.51
Return On Networth /Employed(%)23.1133.4339.19
Return On Assets (%)17.6623.226.9
Total Debt / Equity(X)0.050.070.01
Asset Turnover Ratio (%)1.151.251.37

Particulars

PBDIT Margin (%)

PBIT Margin (%)

PBT Margin (%)

Net PROFIT Margin (%)

Return On Networth / Equity (%)

Return On Networth / Employed(%)

Return On Assets (%)

Total Debt / Equity(X)

Asset Turnover Ratio (%)

Mankind Pharma Ltd Balance Sheet

*All values are in Rs. Cr

Consolidated
Standalone
ParticularsMar 2023Mar 2022Mar 2021
Fixed Assets Annual4,302.243,614.371,659.28
Total Current Assets Annual4,327.874,406.823,906.64
Non Current Assets Annual5,387.584,740.922,466
Total Shareholders Funds Annual7,435.226,155.234,722
Total Assets Annual9,715.459,147.746,372.63

Particulars

Fixed Assets Annual

Total Current Assets Annual

Non Current Assets Annual

Total Shareholders Funds Annual

Total Assets Annual

Mankind Pharma Ltd Earning Calls
Mar 2024
EPS beaten by 0.00 %

Open Demat Account

50years
*By signing up you agree to our terms & conditions
50 Years
of Trust & Legacy
₹0 AMC
for First Year
₹0 Brokerage
on Delivery, Intraday, Currency and NSE F&O

Dividend Pages

PE Ratio

Get Your FAQs Right

As of May 20, 2024, Mankind Pharma Ltd has a market capitalization of 92,029.19 Cr. Value Research classifies it as a Large-Cap company.

Yes, Mankind Pharma Ltd is debt-free with a debt-to-equity ratio of 0.02.

In FY 2023, Mankind Pharma Ltd recorded a total revenue of approximately 10,334.77 Cr marking a significant milestone in the company's financial performance.

Mankind Pharma Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately Infinity% and 0.1% annually, respectively..

Mankind Pharma Ltd's current PE ratio is 48.11.

Mankind Pharma Ltd's ROCE averaged 25.6% from the FY ending March 2022 to 2024, with a median of 25.4%. It peaked at 28.8% in March 2022, reflecting strong capital efficiency over the period..

Mankind Pharma Ltd's latest EBIT is Rs. 2,432.89 Cr, surpassing the average EBIT of Rs. 2,060.6 Cr over the 5 years..